|1.||Ivanovska, Nina: 4 articles (03/2015 - 11/2008)|
|2.||Jiang, Tao: 4 articles (09/2014 - 12/2006)|
|3.||Yu, Yan: 4 articles (03/2009 - 03/2003)|
|4.||Dong, Ning: 4 articles (03/2009 - 03/2003)|
|5.||Gyurkovska, Valeriya: 3 articles (03/2015 - 01/2009)|
|6.||Dimitrova, Petya: 3 articles (08/2014 - 11/2008)|
|7.||Priebe, Waldemar: 3 articles (06/2012 - 02/2008)|
|8.||Cao, Jun: 3 articles (01/2010 - 12/2006)|
|9.||Huang, Chen: 3 articles (01/2010 - 12/2006)|
|10.||Yao, Yong-ming: 3 articles (07/2006 - 03/2003)|
12/01/2012 - "In vivo bioluminescence images showed that tumor growth was dramatically reduced in the AG490 group. "
04/01/2004 - "In this setting, combined exposure to an EGFR blocker and Stat-3 blocker (AG490) results in significantly greater tumor growth inhibition than either agent alone. "
11/05/2015 - "Moreover, in tumor microenvironment of mice treated with AG490, the accumulation of anti-tumor leukocytes such as CD8(+) T-cells, M1 macrophages, and NK cells was apparently exaggerated with the reciprocal reduction of regulatory T cells. "
11/05/2015 - "AG490 treatment significantly suppressed subcutaneous tumor growth, compared with control. "
09/01/2014 - "Moreover, AG490 or JAK2 gene knockdown greatly suppressed tumor invasion and progression in the U87MG-EGFRvIII orthotopic models. "
04/01/2015 - "In cirrhosis rats, AG490 inhibited intrahepatic fibrosis, angiogenesis and inflammation. "
04/01/2015 - "AG490 effectively inhibited JAK2/STAT3 signalling and its downstream cytokines and provided protective effects by decreasing splanchnic neovascularization and inflammation and by attenuating portal pressure and hyperdynamic splanchnic circulation. "
01/01/2016 - "Fig. 1 in this manuscript was reproduced in its entirety from the following study: Gyurkovska V, Stefanova T, Dimitrova P, Danova S, Tropcheva R and Ivanovska N: Tyrosine kinase inhibitor tyrphostin AG490 retards chronic joint inflammation in mice. "
08/01/2014 - "Tyrosine kinase inhibitor tyrphostin AG490 retards chronic joint inflammation in mice."
01/01/2009 - "Herein, we investigate the effects of tyrphostin AG-490 on the early inflammation and on the late renal injury provoked by zymosan injection. "
|3.||Autoimmune Diseases (Autoimmune Disease)
05/15/1999 - "We have further tested the in vivo effects of tyrphostin B42 in experimental allergic encephalomyelitis, a Th1 cell-mediated autoimmune disease. "
08/01/2014 - "Tyrphostin AG490 is a Janus kinase (JAK) 2 inhibitor that is clinically used as an anticancer agent and is also effective in various models of inflammatory and autoimmune diseases. "
01/01/2013 - "Tyrphostin AG490 is a potent Jak-Stat TKi shown effective in the prevention of allograft transplant rejection, experimental autoimmune disease, as well as the treatment of cancer. "
|4.||Multiple Organ Failure (MODS)
11/01/2008 - "In the present study, we have investigated the effects of tyrphostin AG-490, on the development of multiple organ failure induced by i.p. "
11/01/2008 - "In conclusion, the administration of tyrphostin AG-490 in zymosan-induced nonseptic shock significantly improved the rate of survival and lead to less exerted signs of multiple organ failure."
08/01/2010 - "AG490 also inhibits extracellular release of HMGB1 from macrophages and prevents an increase in serum HMGB1 levels during sepsis. "
03/01/2003 - "Thirty-eight male Wistar rats were randomly divided into four groups as follows: normal control group (n=6), postburn sepsis group (n=12), AG490 treatment group (n=10) and Rapamycin (RPM) treatment group (n=10). "
03/15/2015 - "Our data suggest that tyrphostin AG490 diminished the degree of inflammation starting in peritoneal cavity and minimized liver dysfunction thus representing one approach for better outcome of sepsis conditions. "
03/01/2009 - "A total of 98 male Wistar rats were randomly divided into 4 groups as follows: (1) normal control group (n = 10); (2) cecal ligation and puncture (CLP) group (n = 40), which was further divided into 2, 6, 24, 48-hour post-CLP groups; (3) AG490 (8.0 mg/kg, Calbiochem, La Jolla, CA) treatment group (n = 24), which was further divided into 2, 6, 24, 48-hour post-CLP groups; (4) rapamycin (0.4 mg/kg, Calbiochem, Calbiochem, La Jolla, CA) treatment group (n = 24), which was further divided into 2, 6, 24, 48-hour post-CLP groups; CLP was performed to induce experimental sepsis. "
03/01/2003 - "Using a sepsis model of cecal ligation and puncture (CLP), 98 male Wistar rats were randomly divided into normal control group (n=10), CLP group (n=40), AG490 treatment group (n=24), and Rapamycin (RPM) treatment group (n=24). "
|6.||Nitric Oxide Synthase (NO Synthase)
|7.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|9.||2- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- one
|10.||Protein Kinases (Protein Kinase)
|2.||Homologous Transplantation (Allograft)
|5.||Heterologous Transplantation (Xenotransplantation)